Nerinetide

Summary

Nerinetide (CHEMBL502630) is a phase-3 clinical-stage protein; indicated across 3 conditions including stroke disorder and brain ischemia.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Protein
• Indications: 3 conditions
• Clinical trials: 5

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL502630
Name	Nerinetide
Type	Protein
Max phase	3

Also known as: FN-023, FN023, NA-1, Nerinetida, Nerinetide, Tat-nr2b9c, YGRKKRRQRRR-KLSSIESDV, NERINETIDE

Parent form; salt/anhydrous children: CHEMBL4594282, CHEMBL4594283

Patent coverage: 77 distinct patent families (164 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: Disks large homolog 4.

Bioactivity

ChEMBL activities: 4 potent at pChembl ≥ 5 of 5 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
DLG4	5.92	Kd	1200	nM	CHEMBL_ACT_29189272
DLG4	5.36	Ki	4400	nM	CHEMBL_ACT_2374207
DLG4	5.36	Ki	4400	nM	CHEMBL_ACT_5305102
DLG4	5.01	Ki	9800	nM	CHEMBL_ACT_2374206

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

3 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
stroke disorder	3	MONDO:0005098	EFO:0000712
brain ischemia	3	MONDO:0005299	HP:0002637

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 5.

Phase distribution

Phase	Trials
PHASE3	3
PHASE2	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02315443	PHASE3	COMPLETED	Field Randomization of Nerinetide (NA-1) Therapy in Early Responders
NCT02930018	PHASE3	COMPLETED	Safety and Efficacy of Nerinetide (NA-1) in Subjects Undergoing Endovascular Thrombectomy for Stroke
NCT04462536	PHASE3	COMPLETED	Efficacy and Safety of Nerinetide in Participants With Acute Ischemic Stroke Undergoing Endovascular Thrombectomy Excluding Thrombolysis
NCT00728182	PHASE2	COMPLETED	Evaluating Neuroprotection in Aneurysm Coiling Therapy
NCT02056574	PHASE2	WITHDRAWN	Safety and Efficacy Study of a Single Dose of NA-1 in Patients Undergoing Endovascular Repair of Ruptured Aneurysms

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).